SCPH RSI Chart
Last 7 days
5.8%
Last 30 days
7.2%
Last 90 days
-17.4%
Trailing 12 Months
-56.5%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 17.6M | 0 | 0 | 0 |
2023 | 0 | 0 | 0 | 13.6M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jan 18, 2024 | nokes rachael | acquired | - | - | 41,840 | cfo and treasurer |
Jan 18, 2024 | tucker john h | acquired | - | - | 113,560 | president and ceo |
Jan 02, 2024 | nokes rachael | sold (taxes) | -6,562 | 6.39 | -1,027 | cfo and treasurer |
Jan 02, 2024 | tucker john h | sold (taxes) | -31,579 | 6.39 | -4,942 | president and ceo |
Jan 19, 2023 | nokes rachael | acquired | 71,838 | 6.14 | 11,700 | see remarks |
Jan 19, 2023 | tucker john h | acquired | 409,323 | 6.14 | 66,665 | president and ceo |
Nov 25, 2022 | orbimed advisors llc | bought | 4,002,500 | 5.25 | 762,380 | - |
Oct 10, 2022 | 5am partners iv, llc | sold | -1,866,730 | 4.09 | -456,413 | - |
Oct 10, 2022 | 5am partners iv, llc | sold | -77,779 | 4.09 | -19,017 | - |
Oct 10, 2022 | 5am partners iv, llc | sold | -355,977 | 4.09 | -87,036 | - |
Which funds bought or sold SCPH recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | added | 48.47 | 28,254 | 177,994 | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -38.92 | -15,228 | 14,573 | -% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | sold off | -100 | -79,629 | - | -% |
May 15, 2024 | DEUTSCHE BANK AG\ | added | 806 | 62,034 | 71,947 | -% |
May 15, 2024 | SHERBROOKE PARK ADVISERS LLC | new | - | 72,398 | 72,398 | 0.01% |
May 15, 2024 | BARCLAYS PLC | reduced | -48.84 | -147,000 | 102,000 | -% |
May 15, 2024 | Laurion Capital Management LP | sold off | -100 | -262,544 | - | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | reduced | -13.19 | -62,279 | 141,961 | -% |
May 15, 2024 | J. Goldman & Co LP | reduced | -20.36 | -3,191,290 | 5,615,600 | 0.18% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | reduced | -47.02 | -1,288,390 | 949,202 | -% |
Unveiling Scpharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Scpharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Scpharmaceuticals Inc News
Income Statement (Quarterly) | ||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 |
Revenue | 0.1% | 6,102 | 6,096 | 3,796 | 1,638 | 2,063 |
Cost Of Revenue | 0.7% | 1,785 | 1,773 | 1,079 | 354 | 605 |
Operating Expenses | 2.8% | 21,958 | 21,353 | 18,635 | 15,384 | 13,617 |
S&GA Expenses | 7.4% | 17,447 | 16,242 | 14,135 | 12,096 | 10,896 |
R&D Expenses | -18.3% | 2,726 | 3,338 | 3,421 | 2,934 | 2,116 |
Interest Expenses | 0.4% | 2,101 | 2,092 | 2,060 | 2,010 | 1,961 |
Net Income | -2.1% | -14,108 | -13,812 | -15,634 | -14,154 | -11,210 |
Net Income Margin | 18.8% | -3.27* | -4.03* | - | - | - |
Free Cashflow | -17.1% | -17,738 | -15,151 | -13,451 | -14,141 | -16,494 |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -17.0% | 78.00 | 94.00 | 106 | 114 | 127 | 124 | 48.00 | 59.00 | 69.00 | 79.00 | 88.00 | 94.00 | 100 | 109 | 117 | 124 | 80.00 | 77.00 | 87.00 | 83.00 | 88.00 |
Current Assets | -17.7% | 77.00 | 93.00 | 104 | 114 | 127 | 123 | 47.00 | 58.00 | 68.00 | 78.00 | 86.00 | 92.00 | 99.00 | 108 | 116 | 123 | 79.00 | 76.00 | 85.00 | 82.00 | 86.00 |
Cash Equivalents | 24.8% | 58.00 | 47.00 | 35.00 | 71.00 | 75.00 | 71.00 | 41.00 | 41.00 | 52.00 | 74.00 | 80.00 | 75.00 | 76.00 | 72.00 | 44.00 | 79.00 | 76.00 | 73.00 | 84.00 | 80.00 | 84.00 |
Inventory | 8.3% | 10.00 | 9.00 | 7.00 | 6.00 | 4.00 | 1.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net PPE | -10.3% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities | -5.9% | 54.00 | 57.00 | 57.00 | 51.00 | 52.00 | 52.00 | 17.00 | 19.00 | 20.00 | 23.00 | 24.00 | 25.00 | 25.00 | 27.00 | 27.00 | 26.00 | 25.00 | 26.00 | 29.00 | 20.00 | 17.00 |
Current Liabilities | -6.2% | 12.00 | 13.00 | 11.00 | 7.00 | 8.00 | 7.00 | 17.00 | 16.00 | 14.00 | 15.00 | 14.00 | 12.00 | 10.00 | 9.00 | 7.00 | 6.00 | 5.00 | 5.00 | 8.00 | 14.00 | 10.00 |
Long Term Debt | 1.5% | 39.00 | 39.00 | 38.00 | 38.00 | 37.00 | 37.00 | - | 2.00 | 5.00 | 7.00 | 10.00 | 12.00 | 15.00 | 17.00 | 19.00 | 19.00 | 19.00 | 19.00 | 19.00 | 5.00 | 6.00 |
LT Debt, Current | - | - | - | - | - | - | - | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 7.00 | 5.00 | 2.00 | - | - | - | - | - | 5.00 | 4.00 |
LT Debt, Non Current | -100.0% | - | 39.00 | 38.00 | 38.00 | 37.00 | 37.00 | - | 2.00 | 5.00 | 7.00 | 10.00 | 12.00 | 15.00 | 17.00 | 19.00 | 19.00 | 19.00 | 19.00 | 19.00 | 5.00 | 6.00 |
Shareholder's Equity | -34.0% | 25.00 | 37.00 | 49.00 | 63.00 | 76.00 | 72.00 | 31.00 | 40.00 | 49.00 | 56.00 | 63.00 | 69.00 | 76.00 | 82.00 | 90.00 | 98.00 | 55.00 | 51.00 | 58.00 | 63.00 | 70.00 |
Retained Earnings | -5.0% | -295 | -281 | -267 | -251 | -237 | -226 | -217 | -207 | -197 | -189 | -182 | -175 | -168 | -161 | -153 | -144 | -136 | -129 | -118 | -112 | -105 |
Additional Paid-In Capital | 0.5% | 320 | 319 | 317 | 315 | 314 | 299 | 248 | 248 | 247 | 246 | 245 | 245 | 244 | 244 | 244 | 243 | 192 | 181 | 177 | 176 | 176 |
Shares Outstanding | 0.2% | 36.00 | 36.00 | 36.00 | 36.00 | 36.00 | 34.00 | 27.00 | 27.00 | 27.00 | 27.00 | 27.00 | 27.00 | 27.00 | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 274 | - | - | - | 76.00 | - | - | - | 94.00 | - | - | - | 113 | - | - | - | 27.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -17.1% | -17,701 | -15,114 | -13,451 | -14,141 | -16,494 | -11,837 | -8,196 | -7,175 | -7,369 | -7,098 | -5,167 | -6,271 | -8,615 | -9,180 | -4,808 | -5,962 | -7,743 | -14,835 | -5,578 | -3,911 | -6,118 |
Share Based Compensation | 1.7% | 1,440 | 1,416 | 1,281 | 1,179 | 980 | 737 | 785 | 680 | 636 | 637 | 619 | 589 | 521 | 127 | 744 | 621 | 508 | 435 | 333 | 326 | 355 |
Cashflow From Investing | 10.8% | 29,319 | 26,463 | -22,925 | 9,427 | 7,000 | -42,992 | 10,784 | -861 | -12,790 | 4,501 | 9,521 | 5,403 | 12,705 | 36,701 | -29,692 | - | - | - | - | - | - |
Cashflow From Financing | -96.8% | 15.00 | 467 | 68.00 | 611 | 13,704 | 84,601 | -2,477 | -2,416 | -2,479 | -2,458 | - | - | -72.00 | 20.00 | -82.00 | 49,952 | 10,458 | 3,897 | 9,673 | - | 18.00 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Product revenues, net | $ 6,102 | $ 2,063 |
Revenue from Contract with Customer, Product and Service [Extensible Enumeration] | us-gaap:ProductMember | us-gaap:ProductMember |
Operating expenses: | ||
Cost of product revenues | $ 1,785 | $ 605 |
Research and development | 2,726 | 2,116 |
Selling, general and administrative | 17,447 | 10,896 |
Total operating expenses | 21,958 | 13,617 |
Loss from operations | (15,856) | (11,554) |
Other income | 2,972 | 990 |
Interest income | 877 | 1,315 |
Interest expense | (2,101) | (1,961) |
Net loss | $ (14,108) | $ (11,210) |
Net loss per share - basic | $ (0.36) | $ (0.3) |
Net loss per share - diluted | $ (0.36) | $ (0.3) |
Weighted average common shares outstanding - basic | 38,952,131 | 37,800,960 |
Weighted average common shares outstanding - diluted | 38,952,131 | 37,800,960 |
Other comprehensive loss: | ||
Unrealized (loss) gain on short-term investments | $ 1 | $ (24) |
Comprehensive loss | $ (14,107) | $ (11,234) |
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 58,447 | $ 46,814 |
Short-term investments | 29,199 | |
Accounts receivable, net | 5,772 | 4,489 |
Inventory, net | 9,572 | 8,840 |
Prepaid expenses | 2,198 | 2,436 |
Deposits and other current assets | 536 | 1,160 |
Total current assets | 76,525 | 92,938 |
Property and equipment, net | 52 | 58 |
Right-of-use lease assets - operating, net | 1,355 | 1,401 |
Deposits and other assets | 522 | 82 |
Total assets | 78,454 | 94,479 |
Current liabilities | ||
Accounts payable | 2,706 | 4,001 |
Accrued expenses | 9,206 | 8,901 |
Lease obligation - operating, short-term | 184 | 176 |
Other current liabilities | 222 | 56 |
Total current liabilities | 12,318 | 13,134 |
Term loan, long-term | 39,385 | 38,811 |
Derivative liability | 733 | 3,857 |
Lease obligation - operating, long-term | 1,233 | 1,282 |
Other liabilities | 219 | 177 |
Total liabilities | 53,888 | 57,261 |
Commitments and contingencies (Note 12) | ||
Stockholders’ equity | ||
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding | ||
Common stock, $0.0001 par value; 150,000,000 shares authorized as of March 31, 2024; 35,968,510 and 36,054,409 shares issued and outstanding as of December 31, 2023 and March 31, 2024, respectively | 4 | 4 |
Additional paid-in capital | 320,016 | 318,561 |
Accumulated deficit | (295,454) | (281,346) |
Accumulated other comprehensive income | (1) | |
Total stockholders’ equity | 24,566 | 37,218 |
Total liabilities and stockholders’ equity | $ 78,454 | $ 94,479 |